MetaCap

ALX Oncology (ALXO) vs Atrium Therapeutics (RNA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Atrium Therapeutics is the larger company by market cap ($149.3 million vs $137.0 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALXO-49.76%RNA-53.08%
+16%-23%-61%
Feb 27, 20261 yearNov 20, 2026
ALXO-49.76%RNA-53.08%
+8%-24%-56%
Feb 23, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALXO versus RNA key metrics
MetricALXORNA
Share price$1.06$6.92
Market cap$137.03M$149.27M
1-day change+3.92%-0.86%
YTD return-6.19%—
1-year return-25.87%—
5-year return-96.84%—
EPS (TTM)$-0.87$-5.22
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-101.69M—
52-week high$2.66$16.77
52-week low$0.862$6.36
Distance from 52-week high-60.15%-58.74%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+333.96%+217.92%
Average volume1.19M297.20K
Shares outstanding129.27M21.57M
Employees49—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About ALX Oncology

ALXO stock →

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees

About Atrium Therapeutics

RNA stock →

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy.

Health Care · Biotechnology: Pharmaceutical Preparations

ALXO vs RNA FAQ

Which is bigger, ALX Oncology or Atrium Therapeutics?

Atrium Therapeutics (RNA) is larger, with a market capitalization of $149.27M compared with $137.03M for ALX Oncology (ALXO).

Are ALX Oncology and Atrium Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons